Effect of Adjuvant Chemo on Elderly Patients’ Quality of Life

Article

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

FDA Approves Sotorasib/Panitumumab in KRAS G12C-Mutated CRC

Ariana Pelosci
January 16th 2025
Article

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma

Russ Conroy
January 16th 2025
Article

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.

TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer

Russ Conroy
January 16th 2025
Article

Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.

Data from the phase 2b SunRISe-1 study support the NDA for TAR-200 in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with CIS.

FDA Receives NDA for TAR-200 in BCG-Unresponsive High-Risk NMIBC

Russ Conroy
January 15th 2025
Article

Data from the phase 2b SunRISe-1 study support the NDA for TAR-200 in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with CIS.